Anna Mowry compensation by year
Nautilus Biotechnology Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $364,000 | $386,000 | $400,000 | $440,000 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 |
| Option awards | $879,600 | $262,307 | $350,817 | $161,226 |
| Non-equity incentive | $102,375 | $132,012 | — | $110,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $1,200 | $1,200 | $1,200 | $1,200 |
| Total | $1,347,175 | $781,519 | $752,017 | $712,426 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Nautilus Biotechnology, Inc. DEF 14A filed April 28, 2026, accession 0001808805-26-000023, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Nautilus Biotechnology, Inc. filed document, accession 0001808805-26-000023. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 83,334 | — | $2.72 |
| Option | 11,667 | — | $3.78 |
| Option | 43,334 | — | $2.00 |
| Option | 160,000 | — | $1.24 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Nautilus Biotechnology, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Nautilus Biotechnology discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and resignation for good reason | $400,000 | — | — | — |
| Involuntary termination without cause | $200,000 | — | — | — |
| Resignation for good reason, no change in control | $200,000 | — | — | — |
| Change in control and involuntary termination | $400,000 | — | — | — |
Per the Potential Payments Upon Termination or Change in Control table in Nautilus Biotechnology, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Nautilus Biotechnology’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sujal Patel | Chief Executive Officer, President and Secretary | $1,418,556 |
| Parag Mallick | Chief Scientist | $817,646 |
| Anna Mowry · this page | Chief Financial Officer | $712,426 |
Anna Mowry's compensation dossier, Nautilus Biotechnology
You have read Anna Mowry's totals and holdings. The dossier adds each equity grant Nautilus Biotechnology disclosed for Anna Mowry and Nautilus Biotechnology's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Nautilus Biotechnology compensation record
free company briefThis page is one person within Nautilus Biotechnology's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Nautilus Biotechnology's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Nautilus Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order NAUT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.